Kisspeptin-10 is a searched research compound, and its identity is best read through the family it belongs to. The questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that Kisspeptin-10 is an authorized drug or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

The kisspeptins are peptides encoded by the KISS1 gene and processed into shorter fragments that are conventionally named by their amino-acid length — kisspeptin-54, -14, -13, and -10. On that convention, Kisspeptin-10 is a ten-residue kisspeptin fragment; reference databases list it with the molecular formula C63H83N17O14. The kisspeptins act as agonists of the kisspeptin receptor (KISS1R, also known as GPR54), and kisspeptin–GPR54 signalling is described as having a role in initiating the secretion of gonadotropin-releasing hormone (GnRH). Kisspeptin is endogenous. A procurement record should begin with the compound name, that identity, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document; those fields establish identity for reconciliation and do not authorize a route of use.

Research status

Kisspeptin has been investigated in early clinical research. The existence of such investigation documents scientific study; it does not establish that a third-party research material is an authorized drug product, equivalent to any study material, or suitable for human use. This article describes receptor biology as a matter of identity, not as a claim about any effect, and makes no claim about outcomes.

Canadian regulatory context

Kisspeptin-10 is not among the compounds Health Canada named in its April 2026 advisory on unauthorized injectable peptides, but the general principles it sets out still apply to any unauthorized product supplied for research: an unauthorized drug product has not been assessed by Health Canada for safety, efficacy, and quality, and a research-use-only label does not confer legal status — the same principle covered in our note on Canadian regulatory context for research peptides. Vitatide’s research-use wording is a use boundary, not a claim of regulatory authorization, and determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. For Kisspeptin-10 as for any compound, the checks are the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.